1. Impact of SMTP Targeting Plasminogen and Soluble Epoxide Hydrolase on Thrombolysis, Inflammation, and Ischemic Stroke.
- Author
-
Hasumi K and Suzuki E
- Subjects
- Animals, Anti-Inflammatory Agents pharmacology, Anti-Inflammatory Agents therapeutic use, Benzopyrans therapeutic use, Brain Ischemia blood, Brain Ischemia drug therapy, Brain Ischemia pathology, Epoxide Hydrolases drug effects, Epoxide Hydrolases metabolism, Fibrinolysis drug effects, Fibrinolytic Agents pharmacology, Fibrinolytic Agents therapeutic use, Humans, Inflammation blood, Inflammation pathology, Ischemic Stroke blood, Ischemic Stroke pathology, Plasminogen drug effects, Plasminogen metabolism, Pyrrolidinones therapeutic use, Stachybotrys chemistry, Stachybotrys metabolism, Benzopyrans pharmacology, Inflammation drug therapy, Ischemic Stroke drug therapy, Pyrrolidinones pharmacology, Thrombolytic Therapy methods
- Abstract
Stachybotrys microspora triprenyl phenol (SMTP) is a large family of small molecules derived from the fungus S. microspora . SMTP acts as a zymogen modulator (specifically, plasminogen modulator) that alters plasminogen conformation to enhance its binding to fibrin and subsequent fibrinolysis. Certain SMTP congeners exert anti-inflammatory effects by targeting soluble epoxide hydrolase. SMTP congeners with both plasminogen modulation activity and anti-inflammatory activity ameliorate various aspects of ischemic stroke in rodents and primates. A remarkable feature of SMTP efficacy is the suppression of hemorrhagic transformation, which is exacerbated by conventional thrombolytic treatments. No drug with such properties has been developed yet, and SMTP would be the first to promote thrombolysis but suppress disease-associated bleeding. On the basis of these findings, one SMTP congener is under clinical study and development. This review summarizes the discovery, mechanism of action, pharmacological activities, and development of SMTP.
- Published
- 2021
- Full Text
- View/download PDF